STOCK TITAN

BeOne Medicines officer sells 132 ADS at $356

BeOne Medicines’ principal accounting officer sold 132 ADS for tax withholding linked to RSU vesting and now holds 97,929 ordinary shares directly.

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) reported that Principal Accounting Officer Titus B. Ball sold 132 American Depositary Shares on September 1, 2026 at $355.86 per ADS. The sale was effected pursuant to a mandatory tax withholding provision tied to the vesting of a restricted share unit award. Each ADS represents 13 Ordinary Shares, and following this transaction he directly holds 97,929 Ordinary Shares. No Rule 10b5-1 trading plan is reported.

Positive

  • None.

Negative

  • None.
Insider Ball Titus B.
Role Principal Accounting Officer
Sold 132 shs ($47K)
Type Security Shares Price Value
Sale American Depositary Shares F1, F2 132 $355.86 $47K
holding Ordinary Shares -- -- --
Holdings After Transaction: American Depositary Shares — 0 shares (Direct); Ordinary Shares — 97,929 shares (Direct)
Footnotes (2)
  1. F1. Each American Depositary Share represents 13 Ordinary Shares.
  2. F2. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of August 31, 2023, subject to continued service.
ADS sold 132 American Depositary Shares Sale by Principal Accounting Officer on September 1, 2026
Sale price per ADS $355.86 per ADS Price reported for the September 1, 2026 sale
Post-transaction Ordinary Shares held 97,929 Ordinary Shares Direct holdings after the reported transactions
ADS-to-Ordinary Share ratio 1 ADS = 13 Ordinary Shares Relationship between American Depositary Shares and Ordinary Shares
RSU vesting schedule 25% annually 1/4 of the securities vest each anniversary of August 31, 2023, subject to continued service
American Depositary Shares financial
"Each American Depositary Share represents 13 Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
restricted share unit award financial
"in connection with the vesting of a restricted share unit award previously granted"
mandatory tax withholding financial
"The sale was effected pursuant to a mandatory tax withholding provision"
vesting financial
"1/4th of the securities will vest on each anniversary of August 31, 2023"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What insider transaction did BeOne Medicines (ONC) report for Titus B. Ball?

BeOne Medicines reported that Principal Accounting Officer Titus B. Ball sold 132 American Depositary Shares on September 1, 2026 at $355.86 per ADS, in a transaction described as a sale in the open market or a private transaction.

Why were the 132 ADS sold by the BeOne Medicines (ONC) officer?

The 132 ADS sale was effected under a mandatory tax withholding provision in Titus B. Ball’s restricted share unit award agreement, in connection with the vesting of a restricted share unit award previously granted to him.

How many BeOne Medicines (ONC) shares does Titus B. Ball own after the transaction?

After the reported transaction, Titus B. Ball directly holds 97,929 Ordinary Shares of BeOne Medicines Ltd., as stated in the filing’s post-transaction holdings entry for Ordinary Shares.

What is the relationship between BeOne Medicines (ONC) ADS and Ordinary Shares?

Each American Depositary Share of BeOne Medicines represents 13 Ordinary Shares, according to the filing’s footnote describing the ADS-to-Ordinary Share ratio.

Was the BeOne Medicines (ONC) insider sale made under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for this transaction; the document-level checkbox for such a plan is not marked as being in effect.

What are the vesting terms mentioned for the BeOne Medicines (ONC) RSU award?

The filing states that for the relevant restricted share unit award, 1/4 of the securities vest on each anniversary of August 31, 2023, subject to the reporting person’s continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ball Titus B.

(Last)(First)(Middle)
C/O BEONE MEDICINES I GMBH
AESCHENGRABEN 27, 21ST FLOOR

(Street)
BASEL4051

(City)(State)(Zip)

SWITZERLAND

(Country)
2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Principal Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares97,929D
American Depositary Shares(1)09/01/2026S(2)132D$355.860D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each American Depositary Share represents 13 Ordinary Shares.
2. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of August 31, 2023, subject to continued service.
Remarks:
/s/ Frank Collazo, as Attorney-in-Fact09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)